Search Results

You are looking at 1 - 10 of 25 items for :

  • Methylprednisolone x
Clear All
Open access

Nobuhiro Miyamura, Shuhei Nishida, Mina Itasaka, Hirofumi Matsuda, Takeshi Ohtou, Yasuhiro Yamaguchi, Daisuke Inaba, Sadahiro Tamiya and Tetsuo Nakano

, eroded surface; mPSL, methylprednisolone; MS, mineralizing surface; NTX, N-terminal telopeptide; OS, osteoid surface; OV, osteoid volume; PINP, N-terminal propeptides of procollagen type I; TRACP, tartrate-resistant acid phosphatase; TV, total volume

Open access

Misaki Aoshima, Koji Nagayama, Kei Takeshita, Hiroshi Ajima, Sakurako Orikasa, Ayana Iwazaki, Hiroaki Takatori and Yutaka Oki

lobe disappeared on T 1 -weighted MRI ( Fig. 1C ). Treatment The causative drug MTX was discontinued, and then performed biopsies from the sinus, anterior mediastinum, lung, and subcutaneous tissue. We initially administered methylprednisolone

Open access

N Jassam, N Amin, P Holland, R K Semple, D J Halsall, G Wark and J H Barth

treatment modalities, a decision was made to give the patient rituximab. The patient was given the first dose of rituximab and started on methylprednisolone. Subsequent monitoring showed that within 6 months the circulating antibodies disappeared. A >70

Open access

Mike Lin, Venessa Tsang, Janice Brewer, Roderick Clifton-Bligh and Matti L Gild

course of i.v. pulse methylprednisolone 1 g daily. Her visual changes and headaches dramatically resolved. She was then discharged home on oral prednisone 50 mg daily for 10 days with early review. Progress MRI pituitary scan at 2 weeks on therapy showed

Open access

Jonathan Brown and Luqman Sardar

represent a condition known as steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT), also known as Hashimoto’s enecephalopathy. Treatment She was started on methylprednisolone 500 mg for 5 days and then switched to

Open access

Mariana Barbosa, Sílvia Paredes, Maria João Machado, Rui Almeida and Olinda Marques

extraocular movements and no further headaches or vomiting. Dexamethasone was switched to methylprednisolone with tapering dose over 4 weeks and then replaced by hydrocortisone (15 mg/day). Outcome and follow-up At two-month follow-up evaluation, the

Open access

Beverly T Rodrigues, Zulfiquer Otty, Kunwarjit Sangla and Vasant V Shenoy

). She was commenced on 3 days of i.v. methylprednisolone at 80 mg once daily as an in-patient, followed by a tapering regimen of high-dose oral prednisolone for 4 weeks starting at 80 mg daily, in addition to 50 μg of daily T 4 . Figure 2 (A) Pre

Open access

Leanne Hunt, Barney Harrison, Matthew Bull, Tim Stephenson and Amit Allahabadia

was given intravenous (IV) rituximab therapy. Prior to treatment, her serum IgG4 level was measured at 4.43 g/L (6.0–16.0). She received monthly infusions of 1 g IV rituximab with 100 mg IV methylprednisolone between May and July 2014. She remained on

Open access

Andromachi Vryonidou, Stavroula A Paschou, Fotini Dimitropoulou, Panagiotis Anagnostis, Vasiliki Tzavara and Apostolos Katsivas

three consecutive pulses with 1 g methylprednisolone switching to orally 32 mg/day. Methotrexate (10 mg/week) and hydroxychloroquine at a dose of 400 mg/day were also added. In one month, tapering of methylprednisolone was started. Patient was doing well

Open access

Raluca Maria Furnica, Julie Lelotte, Thierry Duprez, Dominique Maiter and Orsalia Alexopoulou

and corticotherapy (methylprednisolone, 32 mg/day) was prescribed, with initial clinical improvement. Table 1 Evolution of the endocrine parameters. Parameters September 2014 – at first diagnosis May 2015 – at 1st appointment in